Kala Pharmaceuticals launches its new eye drops for dry eye disease

Kala Pharmaceuticals have launched a brand new eye formula for dry eye disease named Eysuvis. It is the first and only approved prescription therapy for short-term treatment of signs and symptoms related to dry eye disease. Eysuvis (loteprednoletabonate ophthalmic suspension) 0.25% for dry eye disease launched across the US in national and regional pharmaceutical distribution centers. Patients can now access the treatment through their local retail pharmacies or using home delivery.

“The FDA approval of EYSUVIS as the first prescription therapy specifically developed to address the short-term treatment needs of people living with dry eye disease is a major accomplishment for Kala and an important moment for patients, who have been waiting for an FDA-approved, safe, effective and fast-acting therapy,” said Mark Iwicki, Chairman, President, and Chief Executive Officer of Kala Pharmaceuticals.

The approval of EYSUVIS was based on the results from 4 clinical trials, including 3 Phase 3 trials and 1 Phase 2 trial. Across all trials, the therapy led to significant improvements in dry eye disease symptoms.Its most recent trial, STRIDE 3, had met both of its primary efficacy endpoints. Overall, it showed a great response and will be one of the most significant eye drops to treat dry eye disease.